Puma Biotechnology, Inc. (PBYI) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
PBYI's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
PBYI Revenue Analysis (2014–2025)
As of February 28, 2026, Puma Biotechnology, Inc. (PBYI) generated trailing twelve-month (TTM) revenue of $228.4 million, reflecting exceptional growth of +27.8% year-over-year. The most recent quarter (Q4 2025) recorded $75.5 million in revenue, up 38.6% sequentially.
Looking at the longer-term picture, PBYI's 5-year compound annual growth rate (CAGR) stands at +0.3%, indicating moderate growth over time. The company achieved its highest annual revenue of $272.3 million in 2019.
Revenue diversification analysis shows PBYI's business is primarily driven by Product (89%), and Royalty (11%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY), PBYI has underperformed the peer group in terms of revenue growth. Compare PBYI vs INCY →
Peer Comparison
Compare PBYI's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PBYICurrent | $228M | +27.8% | +0.3% | 16.3% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $228.4M | -0.9% | $170.2M | 74.5% | $37.3M | 16.3% |
| 2024 | $230.5M | -2.2% | $166.1M | 72.1% | $31.0M | 13.4% |
| 2023 | $235.6M | +3.3% | $173.0M | 73.4% | $32.6M | 13.9% |
| 2022 | $228.0M | -9.9% | $172.9M | 75.8% | $23.7M | 10.4% |
| 2021 | $253.2M | +12.5% | $189.5M | 74.8% | $1.3M | 0.5% |
| 2020 | $225.1M | -17.3% | $185.7M | 82.5% | $-30,402,000 | -13.5% |
| 2019 | $272.3M | +8.5% | $235.4M | 86.5% | $-75,595,000 | -27.8% |
| 2018 | $251.0M | +806.1% | $216.4M | 86.2% | $-94,700,000 | -37.7% |
| 2017 | $27.7M | - | $22.1M | 79.8% | $-292,400,000 | -1055.6% |
| 2016 | $0 | - | $-1,149,000 | - | $-276,600,000 | - |
See PBYI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PBYI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PBYI vs AGIO
See how PBYI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PBYI's revenue growth accelerating or slowing?
PBYI revenue is accelerating at +27.8% year-over-year, exceeding the 5-year CAGR of +0.3%. TTM revenue reached $228M. Growth momentum has increased versus prior periods.
What is PBYI's long-term revenue growth rate?
Puma Biotechnology, Inc.'s 5-year revenue CAGR of +0.3% reflects the sustained expansion pattern. Current YoY growth of +27.8% is above this long-term average.
How is PBYI's revenue distributed by segment?
PBYI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.